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Abstract
We consider a class of normal transformation models for clustered failure
time data. The failure time outcomes are assumed to marginally follow a pro-
portional hazards model, while the normally transformed variates allow a shared
frailty. As a result, the model permits population-level interpretation of covari-
ates in the proportional hazards model, but also directly models the correlation
of the transformed failure times. The method allows for varying cluster sizes,
and we are able to predict shared frailties for the transformed failure times.
Predictions of the frailties allow us to evaluate the role of underlying cluster
effects on subjects’ survival. We propose a profile estimation procedure and
derive asymptotic properties under this estimation scheme. Simulation studies
verify finite sample utility. We apply the method to a Children’s Oncology
Group multi-center study of acute lymphoblastic leukemia. The analysis es-
timates marginal treatment effects and examines potential clustering within
treatment institution.
Keywords: Semiparametric normal transformation, frailty model, marginal model,
correlated survival data, proportional hazards model
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1. Introduction
Two major branches of models for correlated survival data are frailty models (Oakes
1989; Murphy 1994, 1995; Parner 1998) and marginal models (Wei, Lin, and Weissfeld
1989; Prentice and Cai 1992; Cai and Prentice 1995). The parameters from these two
approaches have different interpretations and hence are appropriate in different con-
texts. For example, frailty models are used when within cluster inferences are desired.
Frailty models account for dependence by including a multiplicative term (called a
frailty or a random-effect) in the model for the hazard. The multiplicative nature of
the frailty term implies that parameters have interpretations conditional on the value
of the frailty. In contrast, marginal models directly model the marginal failure time
and within cluster correlations are treated as a nuisance. With marginal models, the
correlated nature of the data is often accounted for by using a sandwich-type variance.
The parameters of marginal models have population-average interpretations.
In some correlated survival data settings, practitioners have two primary interests:
assessing the effect of treatment or exposure on the marginal survival distribution
and determining the dependence between subjects. For example, in many multi-
center clinical trials data are clustered within treatment center. Clinical researchers
are interested in the unconditional treatment effect observed in the study, which can
be found via marginal modeling. Although institutions participating in clinical trials
follow trial-specific protocols, differences can still exist between outcomes (Fleiss 1986;
Gray 1994; Jones, Teather, Wang, and Lewis 1998; Senn 1998; Anello, O’Neill, and
Dubey 2005; Vierron and Giraudeau 2007; Logan, Nelson, and Klein 2008; Zheng and
Zelen 2008). The correlation between patients treated at the same institution is an
important component of a multi-center clinical trial analysis.
Our motivating data come from a large multi-center clinical trial for children with
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“higher risk” acute lymphoblastic leukemia. The goal of the study was to evaluate
the effect of different treatments on survival. We are interested in evaluating whether
there existed substantial variation between institutions while concurrently assessing
the efficacy of the new treatments.
To this end we propose a marginalized frailty model, which models the marginal
failure times with the proportional hazards model (Cox 1972) and models the corre-
lation by assuming that normally transformed survival times follow a shared frailty
model. This project extends previous work on normal transformation models (e.g.
Li and Lin (2006); Li, Prentice, and Lin (2008)) in four major ways. First, Li et al.
(2008) use a likelihood method that does not allow for covariates and is restricted to
bivariate data. Our model allows for covariates and varying cluster sizes. Second, Li
and Lin (2006) assume a specific spatial correlation structure on the entire dataset.
Our method explicitly allows for correlated survival times within independent clus-
ters. Third, we establish a likelihood framework for inference for general regression
models for the normally-transformed survival times. Finally, we provide a method
for predicting cluster-level effects, providing information that can be used to evaluate
individual clusters.
The rest of the paper is structured as follows: in Section 2 we define notation and
describe the model; Section 3 provides methods to estimate the marginal survival
parameters, the correlation parameter, and the frailties; we provide a summary of
asymptotic results in Section 4; we outline a model-checking procedure in Section 5;
simulations are presented in Section 6; Section 7 contains an analysis of Children’s
Oncology Group study 1961; and we finish with a brief discussion in Section 8. Reg-
ularity conditions and detailed proofs of theorems are contained in the Appendix.
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2. Model Specification
Let Tij and Cij denote potentially unobserved failure and censoring times for subject
j in cluster i, where j = 1, . . . , ni and i = 1, . . . ,m. The observed data are Xij =
min(Tij, Cij) and ∆ij = I(Tij ≤ Cij). Let Zij(t) denote an external time-dependent
covariate vector (Kalbfleisch and Prentice 2003, page 197) of length p and write its
covariate path up to time t as Z¯ij(t) = {Zij(s) | 0 ≤ s ≤ t}. Assume that Tij,
conditional on the covariate process Z¯ij(Tij), is independent of Cij. Also, assume
that, conditional on each individual’s covariate path, the hazard of Tij follows a
proportional hazards model where λ{t | Z¯ij(t)} is equal to
lim
h→0
h−1P{t ≤ Tij < t+ h | Tij ≥ t, Z¯ij(t)} = λ0(t) exp{β′Zij(t)}. (1)
Here β is a vector of regression coefficients and λ0(t) is an unspecified baseline hazard
function with cumulative hazard function Λ. Equation (1) is a marginal model for each
Tij, hence β has a population-level interpretation not a cluster-specific interpretation.
To model the clustering of the Tij, consider the semiparametric normal transfor-
mation:
T˜ij = Φ
−1[1− S{Tij | Z¯ij(Tij)}], (2)
where Φ is the standard normal distribution function, Φ−1 is the inverse of the stan-
dard normal distribution function, and S is the survival function associated with
Equation (1). By the probability integral transform, 1 − S{Tij | Z¯ij(Tij)} has a
Uniform(0, 1) distribution. It necessarily follows that T˜ij ∼ Normal(0, 1). The trans-
formation takes Tij with support on (0,∞) and transforms it to a standard normal
random variable.
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Denote the correlation of (T˜i1, . . . , T˜ini) with Σi. We propose to model the trans-
formed survival times from Equation (2) with a shared frailty model:
T˜ij =
√
σbi + ij, (3)
where the cluster level frailty bi has a standard normal distribution and the error
terms, ij, are independent and identically distributed N(0, 1 − σ) random variables
that are also independent of bi. We call the class of models described by Equations
(1), (2), and (3) marginalized frailty models. The β parameters in Equation (1) have
marginal interpretation, while σ and bi from Equation (3) characterize the cluster
effect. The term σ can have the interpretation as the proportion of explained variance
shared by members of the same cluster. In the context of a multi-center clinical trial,
the cluster level frailties characterize the center effect. Using this model, Σi will
have an exchangeable structure with diagonal elements equal to 1 and off-diagonal
elements equal to σ.
3. Inference
3.1. Likelihood Function
The survival function for Tij | bi can be written P (Tij > t | bi) = 1−Φ1−σ(t˜−
√
σbi),
with density function fij(t) = φ1−σ(t˜−
√
σbi)f{t | Z¯ij(t)}/φ1−σ(t˜), where t˜ = Φ−1[1−
S{t | Z¯ij(t)}], Φ1−σ is the distribution function for ij, φ1−σ is the density of ij, and
f{t | Z¯ij(t)} is the density associated with Equation (1). Let Φ˜1−σ(t) = 1 − Φ1−σ(t)
and X˜ij = Φ
−1[1 − S{Xij | Z¯ij(Xij)}]. Here X˜ij is a potentially censored version
of T˜ij (Equation (2)). The semiparametric normal transformation is monotone and
thus preserves censoring patterns. The likelihood based on the observed data can be
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written
L(σ,β,Λ) =
m∏
i=1
∫ ni∏
j=1
Φ˜1−σ(X˜ij −
√
σbi)
1−∆ij [λ0(Xij) exp{β′Zij(Xij)}]∆ij
×(exp[
∫ Xij
0
exp{β′Zij(s)} dΛ(s)]φ1−σ(X˜ij −
√
σbi)/φ1−σ(X˜ij))∆ij dΦ(bi)
=
m∏
i=1
∫ ni∏
j=1
[f{Xij | Z¯ij(Xij)}/φ1−σ(X˜ij)]∆ij
×φ1−σ(X˜ij −
√
σbi)
∆ij Φ˜1−σ(X˜ij −
√
σbi)
1−∆ij dΦ(bi).
Conveniently, L(σ,β,Λ) has a closed form expression proportional to a product
of multivariate normal terms. To simplify the presentation, define ∆i =
∑ni
j=1 ∆ij,
order the observations such that ∆i1 = . . . = ∆i∆i = 1, and let X˜
∆i
i = (X˜i1, . . . , X˜i∆i)
and X˜ni−∆ii = (X˜i∆i+1 , . . . , X˜ini).
Then L(σ,β,Λ) can be written
m∏
i=1
φ∆iu (X˜
∆i
i )Φ˜
ni−∆i
c (X˜
ni−∆i
i | X˜∆ii )
ni∏
j=1
[f{Xij | Z¯ij(Xij)}/φ1−σ(X˜ij)]∆ij ,
where φ∆iu is the multivariate normal density corresponding to its argument and
Φ˜ni−∆ic is the multivariate normal survival function corresponding to its argument.
The distribution of each of the arguments will be outlined below. Let Σi be the co-
variance matrix for the transformed failure times. Write Σi as a partitioned matrix:
Σi =
(
Σi11 Σi12
Σi21 Σi22
)
,
where Σi11 has dimension ∆i × ∆i. The vector X˜∆ii follows a multivariate normal
distribution with mean 0 and covariance matrix Σi11. For the second term of the
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likelihood, X˜ni−∆ii | X˜∆ii is a censored observation from a normal distribution with
mean Σi21Σ
−1
i11X˜
i∆′i
i and covariance matrix Σi22 −Σi21Σ−1i11Σi12.
To shed some light on the likelihood, L(σ,β,Λ), we consider an example likelihood
contribution from a cluster of size two where one subject is observed to be censored
at time CA1 and one subject is observed to fail at time TA2. The covariate process for
each subject is denoted Z¯A1(CA1) and Z¯A2(TA2). The normally transformed observed
failure times are X˜A1 = Φ
−1[1 − S{CA1 | Z¯A1(CA1)}] and X˜A2 = Φ−1[1 − S{TA2 |
Z¯A2(TA2)}]. In this case
Σ =
(
1 σ
σ 1
)
.
The first term of L(σ,β,Λ) can be written
φ1u(X˜A2) = (2pi)
−1/2 exp(−X˜2A2/2) (4)
while the second term can be written
Φ1c(X˜A1) =
∫ ∞
X˜A1
{2pi(1− σ2)}−1/2 exp{−(x− σX˜A2)2/2
√
1− σ2} dx. (5)
Equation (4) is the density of a standard normal random variable, while Equation
(5) corresponds to, conditional on X˜A2, the probability that a Normal(σX˜A2, 1− σ2)
random variable is greater than X˜A1.
3.2. Profile Likelihood Estimation
We propose a profile method to estimate (σ,β,Λ):
Step 1: Estimate β and Λ assuming working independence. Denote these estimates βˆ
and Λˆ.
http://biostats.bepress.com/harvardbiostat/paper104
Marginalized Frailty Models 7
Step 2: Estimate σ as the maximum of L(σ, βˆ, Λˆ). Write this maximum as σˆ.
Formulas for the standard errors of βˆ and Λˆ can be found using a sandwich
formula (Spiekerman and Lin 1998). The standard error of σˆ needs to account for
the variability from βˆ and Λˆ. This can be accomplished using a jackknife resampling
scheme. To maintain the correlated structure of the failure times, the clusters should
be the unit of removal for the jackknife calculations (Cai et al. 1997; Cai and Shen
2000).
This estimation procedure is computationally straightforward. Marginal estimates
of the survival function assuming working independence are available in all standard
computing programs. The likelihood for σ, L(σ, βˆ, Λˆ), is proportional to a product of
multivariate normal terms. The multivariate normal terms can be evaluated quickly
using existing software (e.g. R package mvtnorm).
3.3. Predictions of Shared Frailties
Our marginalized frailty model allows us to estimate the shared frailties, which is
often of interest. In the context of institutional clustering, the bi can provide in-
formation on the results of individual institutions participating in a clinical trial.
Estimates of the bi and their standard errors can be found using Laplace approxi-
mations to the bi’s first two moments. Denote the observed data for the i
th cluster,
(Xi1, . . . , Xini ,∆i1, . . . ,∆ini , Z¯i1(Xi1), . . . , Z¯ini(Xini)), with Ψi. The conditional den-
sity of bi given the observed data Ψi, denoted g(bi | Ψi;σ,β,Λ), can be written
L−1i (2pi)
−1/2 exp(−b2i /2)
ni∏
j=1
[f{Xij | Z¯ij(Xij)}/φ1−σ(X˜ij)]∆ij
×φ1−σ(X˜ij −
√
σbi)
∆ij Φ˜1−σ(X˜ij −
√
σbi)
1−∆ij
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where Li is the likelihood for Ψi | σ,β,Λ. Define ki such that g(bi | Ψi;σ,β,Λ) =
L−1i exp{ki(bi | Ψi;σ,β,Λ)}. Using the Laplace approximations to the first two mo-
ments of g(bi | Ψi;σ,β,Λ) (Booth and Hobert 1998), the predicted estimate and
variance of bi are taken to be:
bˆi = E(bi | Ψi) ≈ arg max
bi
ki(bi | Ψi; σˆ, βˆ, Λˆ) (6)
V (bi | Ψi) ≈ −k¨i(bˆi | Ψi; σˆ, βˆ, Λˆ)−1, (7)
where double superscript dots denote second derivatives.
The prediction of the shared frailties is straightforward and computationally fast,
particularly in contrast to standard gamma frailty algorithms, which can involve
analytically complicated integrals. The expression for ki(bi | σˆ, βˆ, Λˆ,Ψi) involves ni
normal terms and can be maximized using any standard optimization routine. The
estimate of the variance of bi has a closed form expression and can be found by
plugging in relevant estimated quantities.
4. Theoretical Results
The following theorems establish the theoretical properties of (σˆ, βˆ, Λˆ) where their
true values are denoted with (σ0,β0,Λ0).
Theorem 1. Under Conditions C.1 – C.6 in the Appendix, (σˆ, βˆ, Λˆ) converges in
probability to (σ0,β0,Λ0) as m→∞.
Theorem 2. Under Conditions C.1 – C.7 in the Appendix, as m→∞, √m(σˆ− σ0)
and
√
m(βˆ − β0) converge to zero-mean normal distributions and
√
m{Λˆ(t)−Λ0(t)}
converges to a zero-mean Gaussian process.
Detailed proofs can be found in the Appendix. The proofs of both theorems for σˆ
involve accounting for the proposed profile estimation method. These theorems verify
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that σˆ is consistent and asymptotically normal when plug-in estimates of β and Λ
are used in the likelihood function.
To prove that σˆ is consistent we first have to verify that the log-likelihood function
is Hadamard differentiable with respect to Λ0 (van der Vaart 1998). The next step
is to show that the first order terms of a Taylor series expansion of the log-likelihood
around β0 and Λ0 are bounded. The final key step is to prove that the log-likelihood
function with plug-in estimates for β and Λ converges uniformly to the expected value
of the log-likelihood function evaluated at the true values for β and Λ.
The proof of normality for σˆ accounts for the profile estimation scheme by inflating
the variance term to account for using βˆ and Λˆ. The key step of the proof is to show
that the score equation can asymptotically be written as the sum of independent
and identically distributed terms, facilitating the use of the central limit theorem.
To make this argument we need to prove that the score equation for σ is Hadamard
differentiable with respect to Λ0 and that the first order terms of a Taylor series
expansion of the score function around β0 and Λ0 are bounded.
The analytical formula for the variance of σˆ is so complicated that it is of little
computational utility. To evaluate the finite sample variability of σˆ we propose to
use a jackknife resampling scheme. We evaluate the performance of the jackknife by
simulation studies, which are presented in Section 6. The jackknife estimates of the
standard error match well with Monte Carlo estimates of the standard error with
moderate numbers of clusters.
5. Model-checking
In practice, it is often of interest to verify that any assumptions made during modeling
are plausible. We propose a two-step model-checking procedure. As the marginal
survival function is modeled using proportional hazards regression, a natural first
Hosted by The Berkeley Electronic Press
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model-checking step is to verify that the associated regression assumptions are not
violated. In our application, we use the method of Grambsch and Therneau (1994),
though there have been many other methods proposed, such as Lin, Wei, and Ying
(1993). Next, provided that the proportional hazards model fit is adequate, the
assumption that the transformed failure times follow a shared frailty model (Equation
(3)) can be checked.
Recall that S{· | Z¯ij(Tij)} is the survival function associated with the marginal
survival time Tij. If S is estimated well, with estimate denoted Sˆ, the probability
integral transform indicates that it should be the case that Φ−1{1− Sˆ(Tij | Z¯ij(Tij))}
approximately follows a standard normal distribution. In verifying the assumptions
of Equation (3), we need to check that the estimates of the frailties are normally dis-
tributed. To this end, let zi = bˆi/
√
V (bˆi), where bˆi and V (bˆi) are defined in Equations
(6) and (7). A simple graphical check of the assumption that the bi are normally dis-
tributed is a quantile-quantile plot (Q-Q plot) of the cumulative distribution function
of the zi.
6. Simulation Results
We conducted a number of simulations to evaluate the efficacy of the proposed
method. The presented simulations have marginal survival times from a propor-
tional hazards model with a constant baseline hazard function equal to 1 and with
two covariates: one Bernoulli(0.5) covariate with parameter equal to log(0.5) (de-
noted β1) and one Uniform(0, 1) covariate with parameter equal to 0.75 (denoted
β2). Censoring times were taken from the Exponential(mean=3) distribution and
produced about a 25% censoring rate. Clustering was induced through generating
survival times using Equation (3). The precision of σˆ is determined by the number of
clusters, while the precision of the predicted frailties is determined by the sample size
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in individual clusters. Each simulation is based on 500 replications. We summarize
results for simulated datasets with 30, 60, and 90 clusters. The individual clusters
sizes either varied between 2 and 10 with a median size of 3, or varied between 10
and 50 with median cluster size 17.
Simulation results are presented in Table 1. Even with small cluster sizes the
estimates of σ are relatively unbiased and the jackknife standard errors match well
with the Monte Carlo standard errors. For example, in a simulation of 30 clusters
with median cluster size 3 the average estimate for σ is 0.531 (truth = 0.5), while in
a simulation of 90 clusters with median cluster size 3 the average estimate for σ is
0.512.
The jackknife estimates of the standard errors for β1 and β2 are closer to the
Monte Carlo standard errors than the sandwich-based standard errors for almost all
the simulations. For example, in a simulation of 30 clusters with median size 3, the
jackknife standard error of β2 is 0.400, which is very close to the Monte Carlo standard
error of 0.403, while the sandwich-based standard error is 0.366. In a simulation of 60
clusters with median size 17, the Monte Carlo and jackknife standard error estimates
of β1 are 0.079 and the sandwich-based standard error estimate is 0.077.
With respect to the frailty estimates, the median relative bias decreases and the
likelihood-based standard error and the Monte Carlo standard error approach one as
the individual cluster sizes increase. For example, in a simulation of 90 clusters with
median cluster size 3 the median relative bias was -0.032 and in a simulation of 30
clusters with median size 3 the likelihood-based standard errors have an average value
of 0.911.
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7. Data Application: Children’s Oncology Group Study 1961
We apply our method to a Children’s Oncology Group study (protocol number 1961)
(Seibel et al. 2008). The study population included 460 children with enlarged livers.
The goal of this study was to determine whether increasing the intensity of therapy
by increasing duration or strength for “higher risk” acute lymphoblastic leukemia
patients would improve survival. To evaluate the relative benefit or harm for each
type of intensification, a 2x2 factorial design with block randomization of patients
was used. The distribution of subjects with enlarged livers among the four arms is
presented in Table 2. We focus on the overall survival endpoint.
We present regression results for an analysis with a marginal survival model con-
taining covariates for strength and duration of treatment in Table 3. We note that
there was no evidence of a duration by strength interaction in the initial analysis of
the entire dataset (Seibel et al. 2008) or in this enlarged liver subset. The p-value
for increased strength of treatment is marginally significant (p-value = 0.056, using
sandwich standard error) and indicates that increased strength of treatment may be
associated with improved survival. The p-value for increased duration of treatment is
marginally significant (p-value = 0.063, using sandwich standard error) and indicates
that duration strength of treatment may be associated with worsened survival. For
both survival parameters, the sandwich-based standard error and jackknife standard
error estimates that account for clustering within institutions provide smaller stan-
dard error estimates than the na¨ıve method assuming independence. The estimate
for σ is 0.171 with a standard error of 0.152.
We also include results for a larger survival model that includes gender and po-
tential prognostic factors age and platelet count at diagnosis. Regression results are
summarized in Table 3. The p-values for increased strength (p-value = 0.067, using
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sandwich standard error) and increased duration (p-value = 0.071, using sandwich
standard error) are slightly larger in this larger model, but the direction of the effect
remains the same. None of the p-values for gender, age, or platelets at diagnosis is
significant. The estimate of σ increases slightly to 0.175 with standard error of 0.144.
We predicted the frailties for each of the institutions in the sample using the
treatment only survival model. A summary of the distributions of the predictions can
be found in Figure 1. The mean of the frailties is close to zero (0.024). A Q-Q plot
with standardized predicted frailties compared to theoretical normal quantiles and
the smoothed density of the predicted frailties indicate that the normal assumption
in approximately satisfied.
We also provide a scatter plot of the predicted frailties and the number of patients
enrolled at each institution in Figure 2. In general, it appears that the predicted
frailties are larger with larger sample sizes. It may be the case that institutions with
more patients have more practice with a trial protocol, which could lead to better
performance.
The two most extreme standardized frailties in the Q-Q plot are marked at the
bottom of Figure 1. The same institutions are marked in Figure 2. These institutions
have more negative predicted frailty values than might be expected given the trends
in the rest of the data. This might be due to the worse than normal outcomes in
these two institutions. Specifically, among the 460 patients in this subset, 14.8% have
died. However, in the institution with 22 patients, the failure rate was 27.3% and, in
the institution with 10 patients, the failure rate was 60%.
8. Discussion
There is a need for flexible survival regression models that allow for marginal interpre-
tations of treatment or exposure, while concurrently evaluating potential clustering.
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The method proposed here establishes a general likelihood framework for this type
of analysis. Marginal treatment or exposure effects are modeled with a proportional
hazards model, while correlated transformed survival times are described by a shared
frailty model.
In future work, we hope to extend the transformation in Equation (3) to normal
distributions with variances that can depend on covariates. This type of model can
allow for more explicit analyses into what is driving differences between clusters.
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Table 1: Summary of Simulation Results
Number of clusters = 30
Median cluster size = 3 Median cluster size = 17
Truth Estimate SEJ SES SEMC Estimate SEJ SES SEMC
σ 0.5 0.531 0.117 – 0.107 0.559 0.070 – 0.067
β1 -0.693 -0.718 0.244 0.217 0.236 -0.709 0.112 0.106 0.109
β2 0.75 0.824 0.400 0.366 0.403 0.770 0.177 0.168 0.179
R. Bias SEL SEMC R. Bias SEL SEMC
Frailties -0.099 0.911 0.759 -0.076 0.797 0.838
Number of clusters = 60
Median cluster size = 3 Median cluster size = 17
Truth Estimate SEJ SES SEMC Estimate SEJ SES SEMC
σ 0.5 0.520 0.081 – 0.076 0.535 0.051 – 0.050
β1 -0.693 -0.710 0.163 0.157 0.157 -0.704 0.079 0.077 0.079
β2 0.75 0.749 0.275 0.260 0.282 0.762 0.125 0.120 0.124
R. Bias SEL SEMC R. Bias SEL SEMC
Frailties -0.040 0.900 0.798 -0.067 0.773 0.886
Number of clusters = 90
Median cluster size = 3 Median cluster size = 17
Truth Estimate SEJ SES SEMC Estimate SEJ SES SEMC
σ 0.5 0.512 0.066 – 0.063 0.528 0.042 – 0.042
β1 -0.693 -0.704 0.133 0.128 0.131 -0.700 0.064 0.063 0.065
β2 0.75 0.773 0.221 0.212 0.229 0.748 0.102 0.100 0.104
R. Bias SEL SEMC R. Bias SEL SEMC
Frailties -0.032 0.896 0.811 -0.055 0.767 0.906
Estimate = average of estimates
SEJ = average of jackknifed based standard errors
SES = average of sandwich-formula based standard errors (only for β)
SEL = average of likelihood based standard errors
SEMC = standard deviation of estimates
R. Bias = median relative bias, where relative bias = bias/parameter estimate
Table 2: Treatment arms for subjects of CCG-1961 with enlarged livers
Arm Strength Duration N
A Standard Standard 119
B Standard Double 104
C Increased Standard 117
D Increased Double 120
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Table 3: Data Analysis Results
Parameter Estimate SEJ SES Na¨ıve SE
Treatment Only Model
Covariates
Increased Strength -0.430 0.231 0.225 0.247
Increased Duration 0.419 0.231 0.226 0.245
Frailty Variance
σ 0.171 0.152 – –
Larger Model
Covariates
Increased Strength -0.418 0.236 0.229 0.247
Increased Duration 0.426 0.247 0.236 0.248
Gender (ref=males) -0.101 0.254 0.243 0.251
Age
1–9 (ref)
10–15 0.415 0.253 0.244 0.262
16+ 0.394 0.491 0.430 0.384
Platelets (×103/mm3)
1–49 (ref)
50–150 0.386 0.303 0.288 0.258
150+ -0.118 0.643 0.568 0.529
Frailty Variance
σ 0.175 0.144 – –
Estimate = log hazard ratios and estimates of σ
SEJ = average of jackknife based standard errors
SES = average of sandwich-formula based standard errors (only for β)
Na¨ıve SE = SE assuming independence
Hosted by The Berkeley Electronic Press
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Figure 1: Left figure: smoothed density of predicted frailties. Right figure: Q-Q plot
of predicted frailties and standard normal distribution quantiles
l
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l l
l
ll l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
5 10 15 20
−
1.
5
−
1.
0
−
0.
5
0.
0
0.
5
Institution Size
Pr
ed
ict
ed
 S
ha
re
d 
Fr
ai
ltie
s
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Appendix A. Regularity Conditions and Notation
Assume the following regularity conditions where τ > 0 is a constant (for example,
study duration):
C.1: β is in a compact subset of Rp
C.2: Λ(τ) <∞
C.3: σ ∈ ν, where ν is a compact subset of (0, 1)
C.4: P (Cij ≥ t∀t ∈ [0, τ ] | Zij) > δc > 0 for j = 1, . . . , ni and i = 1, . . . ,m
C.5: Write Zij(t) = {Zij1(t), . . . , Zijp(t)}. |Zijk(0)|+
∫ τ
0
|dZijk(t)| ≤ BZ <∞ almost
surely for some constant BZ and i = 1, . . . ,m, j = 1, . . . , ni, k = 1, . . . , p
C.6: E log{L(σ1;β,Λ)/L(σ2;β,Λ)} exists for all σ1, σ2 ∈ (0, 1)
C.7: Let Yij(t) = I(Xij ≥ t), K = maxi ni, a⊗0 = 1, a⊗1 = a, a⊗2 = a′a,
Q
(κ)
j (β, t) = m
−1∑m
i=1 Yij(t) exp{β′Zij(t)}Zij(t)⊗κ, q(κ)j (β, t) = EQ(κ)j (β, t),
ηj(β, t) =
q
(1)
j (β,t)
q
(0)
j (β,t)
, %j(β, t) =
q
(2)
j (β,t)
q
(0)
j (β,t)
− ηk(β, t)⊗2 for j = 1, . . . , K.
Assume
∑K
j=1
∫ τ
0
%j(β0, t)q
(0)
j (β0, t)λ0(t) dt is positive definite
Condition C.3 allows us to avoid boundary issues. Condition C.5 assumes that all
the covariates are of bounded variation, which is necessary to ensure the Hadamard
differentiability of the likelihood and score function. Condition C.6 is useful to help
prove that the expected likelihood is maximized at σ0. Condition C.7 is a technical
condition from Spiekerman and Lin (1998) that is needed for the results for βˆ and Λˆ.
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To simplify the presentation of the proofs we define several terms. Define
L∗(σ,β,Λ) =
m∏
i=1
φ∆iu (X˜
∆i
i )Φ˜
ni−∆i
c (X˜
ni−∆i
i | X˜∆ii ),
where L∗(σ,β,Λ) = c∗L(σ,β,Λ) and c∗ does not depend on σ. Let
lm0(σ) = m
−1 logL∗(σ,β0,Λ0), lm(σ) = m
−1 logL∗(σ,β,Λ),
lˆm(σ) = m
−1 logL∗(σ, βˆ, Λˆ), Um0(σ) = ∂lm0(σ)/∂σ, Um0(σ) = ∂lm(σ)/∂σ,
and Uˆm(σ) = ∂lˆm(σ)/∂σ
Expectations are with respect to the true distributions of all random variables in-
volved. Let ‖ ·‖ denote the Euclidean norm and let ‖ ·‖∞ denote the supremum norm
on [0, τ ]. Let BV [0, τ ] denote the class of functions with bounded total variation on
[0, τ ]. Let single superscript dots denote first derivatives and double superscript dots
denote second derivatives.
Appendix B. Proof and Associated Lemmas for Theorem 1
For ease of presentation we state several lemmas used in the proof of Theorem 1, but
defer their proof until the end of the Appendix.
To account for the fact that plug-in estimates of β and Λ are used in the likelihood
for σ, we will need to take a Taylor series expansion of the likelihood of σ around
β0 and Λ0. Since Λ0 is an unspecified function, this expansion will need to include a
functional expansion term. An expansion using Hadamard derivatives is appropriate
for this situation. Hence, in order to use the functional expansion, we need to verify
that the log-likelihood is Hadamard differentiable with respect to Λ, which is done in
Lemma 1.
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Lemma 1. Under conditions C.1–C.5, the log-likelihood lm(σ) is Hadamard differen-
tiable with respect to Λ.
After we have an expansion of the log-likelihood we will need the first order terms
to be bounded by a random variable with finite expectation. We provide this verifi-
cation in Lemma 2.
Lemma 2. Write the Hadamard derivative of lm(σ) with respect to Λ at Π ∈ BV [0, τ ]
as
∫ τ
0
ζm(Λ, σ)(u) dΠ(u) and let ζm(β, σ) = ∂lm(σ)/∂β. Under conditions C.1–C.5,
‖ζm(Λ, σ)‖∞ and ‖ζm(β, σ)‖ are bounded. Expressions for ζm(β, σ) and ζm(Λ, σ) are
provided in the proof.
In order to prove consistency of σˆ we will need to verify the uniform convergence
of the log-likelihood with plug-in estimates of β and Λ to the expected value of the
log-likelihood evaluated at the truth. We accomplish this, using the results of Lemmas
1 and 2, in Lemma 3.
Lemma 3. Under conditions C.1–C.5, as m→∞
sup
σ∈ν
|lˆm(σ)− Elm0(σ)| = op(1).
Finally, in order to verify that σˆ is consistent, we will need to show that the
expected log-likelihood is maximized at the truth, which is done in Lemma 4.
Lemma 4. Under conditions C.1–C.6,
Elm0(σ)− Elm0(σ0) < 0.
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Proof of Theorem 1
The results for βˆ and Λˆ follow from arguments along the lines of Spiekerman and Lin
(1998). We use the results of Lemmas 3 and 4 to prove the result for σˆ.
Since σˆ maximizes lˆm(σ), Lemma 3 implies that
0 ≤ lˆm(σˆ)− lˆm(σ0) = lˆm(σˆ)− lˆm(σ0) + Elm0(σ0)− Elm0(σ0)
= lˆm(σˆ)− Elm0(σ0) + op(1).
Therefore Elm0(σ0) ≤ lˆm(σˆ)+op(1). Subtract Elm0(σˆ) from each side of the inequality
to write
Elm0(σ0)− Elm0(σˆ) ≤ lˆm(σˆ)− Elm0(σˆ) + op(1)
≤ sup
σ∈ν
|lˆm(σ)− Elm0(σ)|+ op(1) = op(1), (8)
where the last equality comes from Lemma 3.
Take σ such that |σ − σ0| ≥ ε for any fixed ε > 0. By Lemma 4 there must exist
some γε > 0 such that Elm0(σ) + γε < Elm0(σ0). It follows that P (|σˆ − σ0| ≥ ε) ≤
P{Elm0(σˆ)+γε < Elm0(σ0)}. Equation (8) implies that P{Elm0(σˆ)+γε < Elm0(σ0)}
converges to 0 as m→∞. Therefore P (|σˆ − σ0| ≥ ε) converges to 0 as m→∞.
Appendix C. Proof and Associated Lemmas for Theorem 2
For ease of presentation we state several lemmas used in the proof of Theorem 2, but
defer their proof until the end of the Appendix.
To account for the fact that plug-in estimates of β and Λ are used in the likelihood
and score function for σ, we will need to take a Taylor series expansion of the score
function for σ around β0 and Λ0. We verify that the score function is Hadamard
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differentiable with respect to Λ, which is done in Lemma 5.
Lemma 5. Under conditions C.1–C.5, the score function Um(σ) is Hadamard differ-
entiable with respect to Λ.
After we have an expansion of the score function for σ, we will need the first order
terms to be bounded by a random variable with finite expectation. We provide this
verification in Lemma 6.
Lemma 6. Write the Hadamard derivative of Um(σ) with respect to Λ at Π ∈ BV [0, τ ]
as
∫ τ
0
ξm(σ,Λ)(u) dΠ(u) and let ξm(β, σ) = ∂Um(σ)/∂β. Under conditions C.1–C.5,
‖ξm(σ,Λ)‖∞ and ‖ξm(σ,β)‖ are bounded. Expressions for ξm(σ,β) and ξm(σ,Λ) are
provided in the proof.
Proof of Theorem 2
The result that
√
m(βˆ − β) converges to mean zero normal distribution and that
√
m(Λˆ− Λ0) converges to mean zero Guassian process follows from arguments along
the lines of Spiekerman and Lin (1998). This proof needs to verify that
√
m(σˆ − σ0)
converges to a normal distribution with mean zero after accounting for the extra
variance induced by the profile estimation procedure. The variance of σˆ should be
inflated over a model where β0 and Λ0 are used to take into account the estimation
of βˆ and Λˆ.
First we will show that the score equation associated with lˆm evaluated at σ0
follows a normal distribution. This result coupled with a first order expansion of the
score equation associated with lˆm around σ0 will finish the proof.
Using Lemma 5, a Taylor series expansion of Uˆm(σ) around β0 and Λ0 gives
Uˆm(σ0) = Um(σ0) +
∫ τ
0
ξm(σ0,Λ)(t) d{Λˆ(t)− Λ0(t)}+ ξm(σ0,β)(βˆ − β) +Gm,
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where Gm is a remainder term for the Taylor series. Since Λˆ and βˆ are
√
m-consistent
it can be shown that Gm = op(m
−1/2). Define the pointwise limit of ξm(σ,Λ)(t) as
ξ(σ,Λ)(t) and let ξ(σ,β) = Eξm(σ,β). From Lemma 6, ‖ξ(σ0,Λ)‖∞ and ‖ξ(σ,β)‖
are bounded. It follows that
√
mUˆm(σ0) =
√
mUm(σ0) +
√
m
∫ τ
0
ξ(σ0,Λ)(t) d{Λˆ(t)− Λ0(t)}
+
√
m ξ(σ0,β)(βˆ − β) + op(1). (9)
Using the results of Spiekerman and Lin (1998), we can write Equation (9) as a
sum of independent and identically distributed random variables,
√
m
∑m
i=1 Ξi, where
EΞ1 = 0 and V Ξ1 <∞. The central limit theorem implies that
√
mUˆm(σ0) converges
to a normally distributed random variable with mean zero and variance equal to the
variance of Ξ1.
Next, we take a first order Taylor series expansion of Uˆm(σˆ) around σ0:
Uˆm(σˆ) = Uˆm(σ0) + (σˆ − σ0)Wˆm(σ∗),
where Wˆm(σ) = ∂Uˆm(σ)/∂σ and σ
∗ is between σˆ and σ0. It must be the case that
Uˆm(σˆ) = 0 since σˆ was taken to be the maximum of L(σ, βˆ, Λˆ). Theorem 1 showed
that σˆ consistently estimates σ0, so the the law of large numbers implies that Wˆm(σ
∗)
converges in probability to W (σ0) = limm→∞Wm(σ0). Finally, using the central limit
theorem and Slutsky’s theorem,
√
m(σˆ− σ0) converges to a normal distribution with
mean zero and variance equal to W (σ0)
−2V (Ξ1).
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Appendix D. Proofs of Lemmas
Proof of Lemma 1
Define Yij(t) = I(Xij ≥ t). The log-likelihood can be written
lm(σ) = m
−1
m∑
i=1
log φ∆iu (X˜
∆i
i ) + log Φ˜
ni−∆i
c (X˜
ni−∆i
i | X˜∆ii )
where X˜ij = Φ˜
−1(exp[− ∫ τ
0
Yij(u) exp{β′Zij(u)} dΛ(u)]). By condition C.5 the term
∫ τ
0
Yij(u) exp{β′Zij(u)} dΛ(u)
is Hadamard differentiable. Using multiple iterations of the chain rule for Hadamard
derivatives (van der Vaart 1998, Theorem 20.9), we conclude that lm(σ) is Hadamard
differentiable.
Proof of Lemma 2
First we find expressions for ζm(σ,Λ) and ζm(β, σ), starting with ζm(σ,Λ). To make
the argument more concrete express lm(σ) as a function of Λ by writing lm(σ,Λ) =
lm(σ). Let Γ ∈ BV [0, τ ]. Denote
Hij = exp[−
∫ τ
0
Yij(u) exp{β′Zij(u)} dΛ(u)].
By conditions C.1 and C.2, for j = 1, . . . , ni and i = 1, . . . ,m, Hij > 0 and |X˜ij| <
B∗ <∞ for some constant B∗.
To find the expression for the derivative, take a Taylor series expansion of lm{σ,Λ+
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t(Γ− Λ)} around t = 0 and evaluate the result at t = 1. The final expression is
lm(σ,Γ) = lm(σ,Λ) +
∫ τ
0
ζm(σ,Λ)(u) d(Λ− Γ)(u),
where ζm(σ,Λ)(u) is equal to m
−1∑m
i=1
∑ni
j=1 D
l
ijYij(u) exp{β′Zij(u)}Hij and Dlij is
equal to
(∆ij[φ
∆i
u (X˜
∆i
i )
−1{∂φ∆iu (X˜∆ii )/∂X˜ij}] + (1−∆ij)[Φ˜ni−∆ic (X˜ni−∆ii | X˜∆ii )
−1
×{∂Φ˜ni−∆ic (X˜ni−∆ii | X˜∆ii )/∂X˜ij}])
ni∑
j=1
∂Φ−1(Hij)/∂Hij.
Therefore the Hadamard derivative for Π ∈ BV [0, τ ] is ∫ τ
0
ζm(σ,Λ)(u) dΠ(u). Direct
calculation verifies that ζm(σ,β) is equal to
m−1
m∑
i=1
ni∑
j=1
Dlij[
∫ τ
0
Yij(u)Zij(u) exp{β′Zij(u)} dΛ(u)]Hij.
We need to check whether each of the terms in Dlij is bounded and also that the
terms unique to ζm(σ,β) and ζm(σ,Λ) are bounded. First,
φ∆iu (X˜
∆i
i ) = (2pi)
−∆i/2 det(Σi11)−1/2 exp(−X˜∆
′
i
i Σ
−1
i11X˜
∆i
i /2) > 1/B1 > 0
for some constant B1 since for X˜ij ∈ X˜∆ii , |X˜ij| < B∗. Therefore, for i = 1, . . . ,m,
φ∆iu (X˜
∆i
i )
−1 < B1 <∞.
Let wα(j) denote the vector of length α where the j
th element is 1 and the rest
of the vector is 0. Using the chain rule, for j = 1, . . . ,∆i and i = 1, . . . ,m,
∂φ∆iu (X˜
∆i
i )/∂X˜ij = −X˜∆
′
i
i Σ
−1
i11w∆i(j)φ
∆i
u (X˜
∆i
i ).
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The multivariate normal density φ∆iu (X˜
∆i
i ) is bounded and for X˜ij ∈ X˜∆ii , |X˜ij| < B∗.
Hence, for j = 1, . . . ,∆i and i = 1, . . . ,m, |∂φ∆iu (X˜∆ii )/∂X˜ij| < B2 < ∞ for some
constant B2.
Next consider Φ˜ni−∆ic (X˜
ni−∆i
i | X˜∆ii ), which for i = 1, . . . ,m is equal to
∫
Mi
(2pi)ni−∆i det(Σ˜i) exp{(tni−∆i − µ˜i)′Σ˜
−1
i (t
ni−∆i − µ˜i)/2} dtni−∆i
where Mi = {t(∆i+1) > X˜i,(∆i+1), . . . , tni > X˜i,ni}, tni−∆i = (t(∆i+1), . . . , tni), Σ˜i =
Σi22 − Σ′i21Σ−1i11Σi12, and µ˜i = Σi21Σ−1i11X˜∆ii . Since |X˜ij| < B∗ for X˜ij ∈ X˜ni−∆ii , it
must be the case that for i = 1, . . . ,m. |Φ˜ni−∆ic (X˜ni−∆ii | X˜∆ii )−1| < B3 <∞ for some
constant B3.
Let tni−∆ij be equal to t
ni−∆i but with the component corresponding to (j−∆i)th
component replaced by X˜ij. Let t
ni−∆i
−j be equal to t
ni−∆i but with the (j − ∆i)th
element removed. Let Mi,−j denote Mi but with the (j − ∆thi ) inequality removed.
Consider |∂Φ˜ni−∆ic (X˜ni−∆ii | X˜∆ii )/∂X˜ij|, which, for j = ∆i + 1, . . . , ni, i = 1 . . . ,m,
can be written
|
∫
Mi
−(2pi)ni−∆i det(Σ˜i) exp{(tni−∆ij − µ˜i)′Σ˜
−1
i (t
ni−∆i
j − µ˜i)/2} dtni−∆i−j | < B4
for some constant B4 <∞ since |X˜ij| < B∗ for X˜ij ∈ X˜ni−∆ii .
Using the definition of the derivative of an inverse function, ∂Φ−1(Hij)/∂Hij =
−[φ{Φ−1(Hij)}]−1, where φ is the density of the standard normal distribution and
Φ−1 is the inverse of the distribution function of the standard normal distribution.
Since |X˜ij| < B∗, 0 < B5 < Hij < B6 < 1 for some constants B5 and B6. Therefore,
for j = 1, . . . , ni and i = 1, . . . ,m, |∂Φ−1(Hij)/∂Hij| < B7 < ∞ for some constant
B7. By condition C.5, for j = 1, . . . , ni and i = 1, . . . ,m, ‖Yij exp(β′Zij)‖∞ < B8 <
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∞ and ‖ ∫ τ
0
Yij(u)Zij(u) exp{β′Zij(u)} dΛ(u)]‖ < B9 < ∞ for some constants B8
and B9. Hence ‖ζm(σ,Λ)‖∞ and ‖ζm(β, σ)‖ are bounded are bounded by (B1B2 +
B3B4)B7(B8 +B9) <∞.
Proof of Lemma 3
An expansion of lˆm(σ) around Λ0 and β0 can be written:
lˆm(σ) = lm0(σ) + ζm(β, σ)(βˆ − β) +
∫ τ
0
ζm(σ,Λ)(t) d(Λˆ− Λ0)(t) +R,
where R is a remainder term of order op{max(‖Λˆ − Λ0‖∞, ‖βˆ − β0‖)} and ζm(β, σ)
and ζm(σ,Λ)(t) are defined in Lemma 2. Since Λˆ is uniformly consistent and βˆ is
consistent (Spiekerman and Lin 1998), R = op(1). The result follows from the law of
large numbers, the uniform consistency of Λˆ, the consistency of βˆ, and the fact that
‖ζm(β, σ)‖ and ‖ζm(σ,Λ)‖∞ are bounded (Lemma 2).
Proof of Lemma 4
The log-likelihood, lm(σ), can be written as a sum of independent and identically
distributed random variables m−1
∑m
i=1 ϕi(σ). Take σ 6= σ0. The law of large numbers
and Jensen’s inequality imply that Elm0(σ) − Elm0(σ0) = limm→∞ lm0(σ) − lm0(σ0)
which is strictly less than log[E(L∗(σ,β0,Λ0)/L
∗(σ0,β0,Λ0))] = 0.
Proof of Lemma 5
Let N(t, d,µ,Σ†) be defined as (2pi)−d/2 det(Σ†)−1/2 exp{−(t− µ)′(Σ†)−1(t− µ)/2}
[tr{(Σ†)−1W˜d} − {−(t − µ)′(Σ†)−1W˜d(Σ†)−1(t − µ)/2}]/2, where W˜d is the d di-
mensional square matrix with zeros along the diagonal and ones off the diagonal. Let
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0d denote a vector of length d of zeros. The score function can be written
Um(σ) = m
−1
m∑
i=1
φ∆iu (X˜
∆i
i )
−1N(X˜∆ii ,∆i,0
∆i ,Σi11)
+Φ˜ni−∆ic (X˜
ni−∆i
i | X˜∆ii )−1
∫
Mi
N(tni−∆i , ni −∆i, µ˜i, Σ˜i) dtni−∆i .
Using the results of Lemma 1 and multiple iterations of the chain rule for Hadamard
derivatives (van der Vaart 1998, Theorem 20.9), we conclude that Um(σ) is Hadamard
differentiable.
Proof of Lemma 6
First we find expressions for ξm(σ,Λ) and ξm(σ,β), starting with ξm(σ,Λ). To make
the argument more concrete express Um(σ) as a function of Λ by writing Um(σ,Λ) =
Um(σ). Let Γ ∈ BV [0, τ ].
To find the expression for the derivative, take a Taylor series expansion of Um{σ,Λ+
t(Γ − Λ)} around t = 0 and evaluate the result at t = 1. The final expression
is Um(σ,Γ) = Um(σ,Λ) +
∫ τ
0
ξm(σ,Λ)(u) d(Λ − Γ)(u), where ξm(σ,Λ)(u) is equal to
m−1
∑m
i=1
∑ni
j=1D
U
ijYij(u) exp{β′Zij(u)}Hij and
DUij = (∆ij[{∂φ∆iu (X˜∆ii )
−1
/∂X˜ij}N(X˜∆ii ,∆i,0∆i ,Σi11) + φ∆iu (X˜∆ii )
−1
×{∂N(X˜∆ii ,∆i,0∆i ,Σi11)/∂X˜ij}] + (1−∆ij)[{∂Φ˜ni−∆ic (X˜ni−∆ii | X˜∆ii )
−1
/∂X˜ij}
×
∫
Mi
N(tni−∆i , ni −∆i, µ˜i, Σ˜i) dtni−∆i + Φ˜ni−∆ic (X˜ni−∆ii | X˜∆ii )
−1
×{∂
∫
Mi
N(tni−∆i , ni −∆i, µ˜i, Σ˜i) dtni−∆i/∂X˜ij}])
ni∑
j=1
∂Φ−1(Hij)/∂Hij
Therefore the Hadamard derivative for Π ∈ BV [0, τ ] is ∫ τ
0
ξm(σ,Λ)(u) dΠ(u). Direct
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calculation verifies that ξm(σ,β) is equal to
m−1
m∑
i=1
ni∑
j=1
DUij [
∫ τ
0
Yij(u)Zij(u) exp{β′Zij(u)} dΛ(u)]Hij.
In Lemma 2 we showed that, for i = 1, . . . ,m, |φ∆iu (X˜∆ii )−1| < B1 < ∞ and
|Φ˜ni−∆ic (X˜ni−∆ii )−1| < B3 <∞.Also, for j = 1, . . . , ni, i = 1, . . . ,m, |∂Φ−1(Hij)/∂Hij| <
B7 <∞, ‖Yij exp(β′Zij)‖∞ < B8 <∞ and ‖
∫ τ
0
Yij(u)Zij(u) exp{β′Zij(u)} dΛ(u)]‖ <
B9 <∞.
We tackle each of the remaining terms. First, using results from Lemma 2, for j =
1, . . . ,∆i, i = 1, . . . ,m, |∂φ∆iu (X˜∆ii )
−1
/∂X˜ij| is equal to |−φ∆iu (X˜∆ii )−2{∂φ∆iu (X˜∆ii )/∂X˜ij}| <
B11 = B
2
1B2 <∞ for some constant B11.
Since Σi11 has an exchangeable structure, tr{Σ−1i11W˜∆i} and det(Σi11)−1/2 are both
bounded by some constantB10 <∞. Therefore for i = 1, . . . ,m, |N(X˜∆ii ,∆i,0∆i ,Σi11)| <
B12 <∞ for some constant B12.
Next, we consider |∂N(X˜∆ii ,∆i,0∆i ,Σi11)/∂X˜ij| for j = 1, . . . ,∆i and i = 1, . . . ,m,
which is equal to
|X˜∆′ii Σ−1i11w∆i(j)N(X˜∆ii ,∆i,0∆i ,Σi11) + X˜∆
′
i
i Σ
−1
i11W˜∆iΣ
−1
i11w∆i(j)φ
∆i
u (X˜
∆i
i )|,
and, by the results of the previous paragraph and the results of Lemma 2, is bounded
by some constant B13 <∞.
Using results from Lemma 2, for j = ∆i + 1, . . . , ni and i = 1, . . . ,m,
|∂Φni−∆ic (X˜ni−∆ii | X˜∆ii )
−1
/∂X˜ij| is equal to
| − Φni−∆ic (X˜ni−∆ii | X˜∆ii )−2{∂Φni−∆ic (X˜ni−∆ii | X˜∆ii )/∂X˜ij}| < B14 = B23B4 <∞
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for some constant B14.
Using similar arguments as above one can directly show that for i = 1, . . . ,m,∫
Mi
N(tni−∆i , ni −∆i, µ˜i, Σ˜i) dtni−∆i < B15 <∞ for some constant B15.
Also, for j = ∆i + 1, . . . , ni and i = 1, . . . ,m,
|∂
∫
Mi
N(tni−∆i , ni −∆i, µ˜i, Σ˜i) dtni−∆i/∂X˜ij
=
∫
Mi,−j
N(tni−∆ij , ni −∆i, µ˜i, Σ˜i) dtni−∆i−j | < B15 <∞
for some constant B16.
Hence ‖ξm(σ,Λ)‖∞ and ‖ξm(β, σ)‖ are bounded are bounded by (B11B12+B1B13+
B14B15 +B3B16)B7(B8 +B9) <∞.
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